Expand all sections

Binimetinib/encorafenib

Braftovi

Extended indication mExtension of indication to include binimetinib in combination with encorafenib for the treatment of
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Binimetinib/encorafenib
Domain Oncology
Reason of inclusion Indication extension
Extended indication mExtension of indication to include binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.
Proprietary name Braftovi
Manufacturer Pfizer

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date October 2023
Expected Registration August 2024
Registration phase Registration application pending
Additional remarks NCT03915951

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.